Advancium is pleased to announce a $30M charitable gift from the Maxine and Stuart Frankel Foundation, of Bloomfield Hills, MI. Of the total contribution, $5M will be allocated to support the activities of CobiCure. https://t.co/Gd68ecKvAI
CobiCure will leverage Deerfield Management's expertise and insights as well as Coridea, a for-profit medical device incubator focused on solutions for cardiac, pulmonary, renal, and neurology conditions. https://t.co/DGRiFbVtay
“I feel a lot of pride for our bold mission to cure rare and life-threatening diseases in children. ” – Mark Veich, President of the Advancium Health Network, interim President of CobiCure https://t.co/7H2MqB4U3X
#ICYMI Mark Veich, President of the Advancium Health Network, interim President of CobiCure, and Executive Director, Deerfield Foundation presented at CSI Frankfurt.
Driven by a deep understanding of the pediatric healthcare market and a passion for bringing life changing technologies to address gaps in care, CobiCure has an initial focus on pediatric cardiovascular conditions Learn more at https://t.co/EkxZP6ESPh
The first condition CobiCure is targeting is functional single ventricle (FSV) disorder. FSV disorder is a rare condition where one of the two ventricles of the heart are malformed, preventing effective pumping of blood. https://t.co/4R59W8G19u
CobiCure is a resident of the Cure at 345 Park Avenue South, a premier healthcare innovation campus located in New York City. As a resident of Cure, CobiCure will have access to leading-edge technology, equipment, and other important resources. https://t.co/6jprah3Ffg
By leveraging a for-profit model with philanthropic investments, CobiCure will provide a viable path to commercialization of life-saving medical devices and other technological innovations. Learn more about CobiCure’s work with Transmural Systems https://t.co/Ia18ge6UuL
Speaking to @Medtech_Insight, one of CobiCure’s founders, Howard Levin explained that the current treatments for FSV disorder are limited. Levin is also CEO of the Deerfield Catalyst, a subsidiary of Deerfield Management and the president of Coridea. https://t.co/yWvxUyDsma
2,000 children a year are born w/ a Functional Single Ventricle. Potential solutions have been traditionally underfunded due to a small commercial market. CobiCure's first investment focuses on the development of a medical device for this heart condition. https://t.co/6jprah3Ffg
@mveich, President of Advancium Health Network and Executive Director, Deerfield Foundation recently presented at @CSIcongress Frankfurt, a conference that provides a comprehensive overview of congenital, structural and valvar heart disease interventions. https://t.co/9ymO6r9aB8
CobiCure was launched through Advancium, an organization dedicated to advancing healthcare services and equity. Advancium supports new ideas, organizations, and initiatives that address underserved patient populations and difficult-to-treat diseases. https://t.co/8K0PEaEnZv
CobiCure’s first investment will focus on the development and commercialization of a medical device for the congenital heart condition, functional single ventricle (FSV) disorder. The device in development was licensed from Transmural Systems. https://t.co/Ia18ge6UuL
CobiCure is based in New York City and is a resident of the Cure, a healthcare innovation campus located in Manhattan. For more information on CobiCure, visit https://t.co/KSlzUAznJP
We're proud to announce the launch of CobiCure LLC, a not-for-profit focused on curing rare, life-threatening diseases in children. Initial collaborators include healthcare investment firm, Deerfield Management and medtech innovator, Coridea. https://t.co/Ia18ge6UuL